GlassScriptPhysician profile
Lauren R Kovacs
NPI 1598062259
$3,680.96
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $683 · 2021: $600 · 2022: $803 · 2023: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $3,064.47 | 2019-2022 | |
| Therapeuticsmd, INC. | $90.35 | 2019-2022 | |
| Allergan, INC. | $83.99 | 2019-2020 | |
| Lupin INC. | $65.85 | 2019-2020 | |
| Abbvie INC. | $65.47 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $54.54 | 2019 | |
| Duchesnay USA Incorporated | $43.15 | 2019 | |
| Avion Pharmaceuticals | $40.24 | 2022 | |
| Amag Pharmaceuticals, INC. | $27.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2022 | |
| Convatec INC. | $22.40 | 2019 | |
| Merck Sharp & Dohme LLC | $17.38 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Mylan Pharmaceuticals INC. | $15.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.87 | 2022 | |
| Exeltis, USA INC. | $14.47 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $14.15 | 2022 | |
| Agile Therapeutics, INC. | $12.39 | 2022 | |
| Scynexis, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Kovacs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.